secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2024-08-20T23:59:59+00:00
Accession:  0001213900-24-071174
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma appoints Hong Zhang as Chairperson and Board member
-------------------------------------------------------------------------

- Hong Zhang appointed Chairperson and director effective Aug 14, 2024; board expands from 5 to 6.
- Ms. Zhang brings 25+ years financial and corporate strategy experience; previous Chairman Dr. Cheng Liu remains on board.
- Compensation: $5,000/quarter as director + $2,500/quarter as Chairperson; expenses reimbursed.
- Company also negotiating consulting agreement with entity owned by Ms. Zhang for Asian strategic initiatives; terms pending approval.
- Press release notes dosing of first patient in Phase I/II trial STARLIGHT-1 for EB103 in R/R B-cell NHL.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024071174/0001213900-24-071174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024071174/ea021197101-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-071174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer